2002 DEA Law Patients 
Cannabis Law Report
JULY 9, 2021
The state of the law on psychedelic substances is in flux. Patients would participate in therapy sessions to prepare for the use of psychedelics, after which the substances would be administered under the guidance and supervision of trained medical professionals. have also passed “Right to Try” laws. Published Via JD Supra.
PrestoDoctor
JULY 16, 2019
The National Organization for the Reform of Marijuana Laws (NORML). When it comes to cannabis reform groups, the National Organization for the Reform of Marijuana Laws is almost always one of the first to come up. According to plaintiff José Belén, “the DEA was told to act with ‘great dispatch’ and with ‘all deliberate speed”.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PrestoDoctor
JULY 16, 2019
The National Organization for the Reform of Marijuana Laws (NORML). When it comes to cannabis reform groups, the National Organization for the Reform of Marijuana Laws is almost always one of the first to come up. According to plaintiff José Belén, “the DEA was told to act with ‘great dispatch’ and with ‘all deliberate speed”.
Cannabis Law Report
APRIL 8, 2022
Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. On May 3, 2021, our study of MDMA-assisted therapy for PTSD achieved successful results for patients with severe, chronic PTSD. Lyle Craker, Ph.D., Source: [link].
Kind Meds (Cannabis Education Blog)
FEBRUARY 7, 2022
The DEA still classifies cannabis as a Schedule I controlled substance, a designation reserved for drugs with no medical value and a high potential for abuse. The governor of New Mexico signed a legalization bill into law in 2021, and residents can now grow and possess cannabis, but it will not be available for retail sale until 2022.
Cannabis Law Report
JULY 12, 2019
Side effects were very prevalent in 79% of all patients taking a refined CBD product, some of which were severe like thrombocytopenia and transaminase elevations in the liver. Review: During an open-label trial of pure CBD with Lennox-Gastaut and Dravet patients, 79% of all patients reported side effects.
Cannabis Law Report
MARCH 25, 2019
CPA’s” PUBLISHER: CANNABIS LAW REPORT. At the present time, state medical and recreational legalization have no impact on federal drug control laws. Although many states have chosen to legalize medical marijuana and four have legalized recreational use, such state actions continue to conflict with federal law.
Expert insights. Personalized for you.
105 
Let's personalize your content